Tenofovir

Higher end-of-treatment hepatitis B e-antigen level correlated with nucleos(t)ide clinical relapse but did not correlate with relapse severity regardless of HBsAg level among patients with chronic hepatitis B virus, according to research.

Long-term tenofovir treatment in pediatric patients with chronic hepatitis B was well tolerated and correlated with a high rate of viral suppression, according to a study presented at the International Liver Congress.

Tenofovir reduced the severity of COVID-19 infection among patients with chronic hepatitis B, according to a presentation at The Digital International Liver Congress.

The CDC released a draft of revised clinical practice guidelines for HIV PrEP and took feedback from clinicians via two webinars held May 24 and 25.

Teva Pharmaceuticals announced the availability and price of the first generic versions of the HIV medications Truvada and Atripla.

Tenofovir alafenamide with emtricitabine and dolutegravir, or TAF/FTC+DTG, and tenofovir disoproxil fumarate, or TDF, and FTC+DTG resulted in similar efficacy to TDF, FTC and efavirenz, or EFV, among people with HIV in South Africa.

Measuring the concentration of tenofovir in a patient’s urine can determine their recent adherence to pre-exposure prophylaxis, or PrEP, for HIV prevention or tenofovir-based ART, according to findings from the Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy, or TARGET, study.

The biggest development in ART in the last several years has been “the explosion of options in single-tablet regimens,” according to Robert M. Grossberg, MD, associate professor of clinical medicine at Albert Einstein College of Medicine and medical director of the Montefiore Center for Positive Living/Infectious Diseases Clinic, both in the Bronx, NY.

There are several principles to keep in mind when choosing treatment regimens for patients coinfected with HIV and hepatitis C virus, according to Carlos Malvestutto, MD, MPH, assistant clinical professor in the division of infectious diseases at The Ohio State University and medical director of the Family AIDS Clinic and Education Services at Nationwide Children’s Hospital.

In this video, Donna Sweet, MD, a professor of internal medicine at the University of Kansas Medical School-Wichita, discusses the latest developments from the International AIDS Conference 2024, including the major PURPOSE study.